Utility of quantitative EEG during sleep as a potential biomarker of Lewy body disease progression
Objective: Objective: To assess whether progression from isolated REM sleep behaviour disorder (iRBD), established Parkinson’s disease (PD) and Dementia with Lewy bodies (DLB) are accompanied…Therapy-associated risk decision making in individuals with multiple system atrophy and Parkinson’s disease, THE YAMSA TRIAL
Objective: This study aimed to quantify the risk willingness of patients suffering from the α-synucleinopathies multiple system atrophy (MSA) and Parkinson's Disease (PD) and identify…An in-vivo study of regional synaptic density loss in patients with Multiple System Atrophy using [11C]UCB-J PET molecular imaging.
Objective: We present preliminary, cross-sectional data, on the in-vivo evaluation of pre-synaptic terminal density in the brain of patients with Multiple System Atrophy (MSA) compared…Clinico-pathological correlations in atypical parkinsonism
Objective: We aim to assess diagnostic accuracy of the Parkinson-plus syndromes (PPS) using the current consensus criteria, whilst identifying the diagnostically most salient clinical features.…Polyneuropathy in Parkinson’s disease: cross-sectional analysis of the Bochum Parkinson Nerve Study cohort
Objective: To describe the prevalence of large-fiber polyneuropathy (PNP) in people with PD and examine differences between subjects with or without PNP. Background: Non-motor symptoms…Predictors of death in Parkinson’s disease
Objective: To investigate how clinical, motor and behavioural characteristics impact on Parkinson mortality in a cohort from a tertiary movement disorders specialty center . Background:…Is a Parkinson’s Sialorrhoea service effective?
Objective: Evaluate the efficacy and tolerance of Botulinum Toxin A (BoNT A) in managing sialorrhoea in People with Parkinsons (PwP)Assess impact on quality of life…How does a diagnosis of Dementia with Parkinson’s influence future care provision?
Objective: To describe the trajectory of Parkinson’s after the onset of dementia including setting of care, frailty levels and mortality rate. Background: Cardiff and Vale…Neuroprotective properties of arylpiperazine-sulphonamides in an in vitro model of Parkinson’s disease
Objective: To investigate the neuroprotective effects of novel arylpiperazine compounds as measured by viability of SH-SY5Y cells in vitro. Background: Parkinson’s disease (PD) is a…Drivers of Health-Related Quality of Life in Parkinson’s Disease: non-motor symptoms and time spent in daily activities
Objective: The purpose of this study was to identify factors associated with health-related quality of life (HRQoL) in people with Parkinson’s Disease (PwP). Background: HRQoL…
- « Previous Page
- 1
- …
- 302
- 303
- 304
- 305
- 306
- …
- 1554
- Next Page »